Marijam Alen, Marijic Pavo, Puggina Anna, Cailloux Olivier, Verelst Frederik, Vicentini Marta, Turriani Elisa, Gkalapi Foteini, Jaidhauser Indra, Rieger Christina, Bonanni Paolo, de Waure Chiara, Rohde Gernot, Tervonen Tommi
GSK, Wavre, Belgium.
GSK, Munich, Germany.
Vaccine. 2025 Aug 13;61:127390. doi: 10.1016/j.vaccine.2025.127390. Epub 2025 Jun 20.
To improve the uptake of respiratory syncytial virus (RSV) vaccination, we used discrete choice experiments (DCEs) to understand the vaccine attributes most important to older adults receiving RSV vaccines and physicians recommending RSV vaccines in Germany and Italy.
The vaccine attributes assessed included the level of protection from lower respiratory tract disease provided in the first and second year, flexibility in time of administration, the possibility for co-administration with one other vaccine, and if the vaccine was recommended in clinical guidelines and/or a national immunization program (NIP). DCE results were used to derive relative attribute importance, minimum acceptable benefits, and predicted choice probabilities.
A total of 999 older adults and 300 physicians were included. The most important vaccine attributes to both groups were the level of protection provided in the first and second year, and the inclusion of the vaccine in a NIP. Older adults and physicians would only consider a vaccine not included in a NIP if the first-year protection was ≥20-27 % higher than that of a vaccine included in the NIP. Co-administration and time of administration had little to no impact. Older adults aged 60-69 years with chronic conditions associated with increased risks of RSV were most likely to accept RSV vaccination (85 %), vs those aged 50-59 years with these conditions (78 %), aged 60-69 years without these conditions (61 %), or aged ≥70 years (65 %) with/without these conditions. Similarly, German and Italian physicians were most likely to recommend a vaccine to adults aged 60-69 years with chronic conditions as well as to those aged ≥70 years.
These results suggest that, to improve RSV vaccine uptake in Germany and Italy, RSV vaccines should remain included in NIPs, and older and physicians should be informed of vaccine protection levels and benefits.
为提高呼吸道合胞病毒(RSV)疫苗的接种率,我们采用离散选择实验(DCE)来了解对德国和意大利接种RSV疫苗的老年人以及推荐RSV疫苗的医生而言最重要的疫苗属性。
评估的疫苗属性包括第一年和第二年提供的针对下呼吸道疾病的保护水平、接种时间的灵活性、与另一种疫苗联合接种的可能性,以及该疫苗是否在临床指南和/或国家免疫规划(NIP)中被推荐。DCE结果用于得出相对属性重要性、最低可接受益处以及预测选择概率。
共纳入999名老年人和300名医生。对两组而言最重要的疫苗属性都是第一年和第二年提供的保护水平,以及该疫苗被纳入NIP。只有当第一年的保护水平比纳入NIP的疫苗高≥20 - 27%时,老年人和医生才会考虑未纳入NIP的疫苗。联合接种和接种时间几乎没有影响。患有与RSV风险增加相关慢性病的60 - 69岁老年人最有可能接受RSV疫苗接种(85%),而患有这些疾病的50 - 59岁老年人(78%)、无这些疾病的60 - 69岁老年人(61%)或有/无这些疾病的70岁及以上老年人(65%)接受率较低。同样,德国和意大利的医生最有可能向患有慢性病的60 - 69岁成年人以及70岁及以上成年人推荐疫苗。
这些结果表明,为提高德国和意大利的RSV疫苗接种率,RSV疫苗应继续纳入NIP,并应告知老年人和医生疫苗的保护水平和益处。